Cited 1 times in
Comparison of high-dose IVIG and rituximab versus rituximab as a preemptive therapy for de novo donor-specific antibodies in kidney transplant patients
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김범석 | - |
dc.contributor.author | 김형우 | - |
dc.contributor.author | 양재석 | - |
dc.contributor.author | 이주한 | - |
dc.contributor.author | 허규하 | - |
dc.contributor.author | 허석재 | - |
dc.date.accessioned | 2023-07-12T03:03:00Z | - |
dc.date.available | 2023-07-12T03:03:00Z | - |
dc.date.issued | 2023-05 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/195482 | - |
dc.description.abstract | De novo donor-specific antibody (dnDSA) is associated with a higher risk of kidney graft failure. However, it is unknown whether preemptive treatment of subclinical dnDSA is beneficial. Here, we assessed the efficacy of high-dose intravenous immunoglobulin (IVIG) and rituximab combination therapy for subclinical dnDSA. An open-label randomized controlled clinical trial was conducted at two Korean institutions. Adult (aged ≥ 19 years) kidney transplant patients with subclinical class II dnDSA (mean fluorescence intensity ≥ 1000) were enrolled. Eligible participants were randomly assigned to receive rituximab or rituximab with IVIG at a 1:1 ratio. The primary endpoint was the change in dnDSA titer at 3 and 12 months after treatment. A total of 46 patients (24 for rituximab and 22 for rituximab with IVIG) were included in the analysis. The mean baseline estimated glomerular filtration rate was 66.7 ± 16.3 mL/min/1.73 m2. The titer decline of immune-dominant dnDSA at 12 months in both the preemptive groups was significant. However, there was no difference between the two groups at 12 months. Either kidney allograft function or proteinuria did not differ between the two groups. No antibody-mediated rejection occurred in either group. Preemptive treatment with high-dose IVIG combined with rituximab did not show a better dnDSA reduction compared with rituximab alone. Trial registration : IVIG/Rituximab versus Rituximab in Kidney Transplant With de Novo Donor-specific Antibodies (ClinicalTrials.gov Identifier: NCT04033276, first trial registration (26/07/2019). © 2023, The Author(s). | - |
dc.description.statementOfResponsibility | open | - |
dc.format | application/pdf | - |
dc.language | English | - |
dc.publisher | Nature Publishing Group | - |
dc.relation.isPartOf | SCIENTIFIC REPORTS | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Graft Rejection | - |
dc.subject.MESH | Graft Survival | - |
dc.subject.MESH | HLA Antigens | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Immunoglobulins, Intravenous / therapeutic use | - |
dc.subject.MESH | Isoantibodies | - |
dc.subject.MESH | Kidney Transplantation* / adverse effects | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Rituximab / therapeutic use | - |
dc.title | Comparison of high-dose IVIG and rituximab versus rituximab as a preemptive therapy for de novo donor-specific antibodies in kidney transplant patients | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Hyung Woo Kim | - |
dc.contributor.googleauthor | Juhan Lee | - |
dc.contributor.googleauthor | Seok-Jae Heo | - |
dc.contributor.googleauthor | Beom Seok Kim | - |
dc.contributor.googleauthor | Kyu Ha Huh | - |
dc.contributor.googleauthor | Jaeseok Yang | - |
dc.identifier.doi | 10.1038/s41598-023-34804-6 | - |
dc.contributor.localId | A00488 | - |
dc.contributor.localId | A01151 | - |
dc.contributor.localId | A06130 | - |
dc.contributor.localId | A03163 | - |
dc.contributor.localId | A04344 | - |
dc.relation.journalcode | J02646 | - |
dc.identifier.eissn | 2045-2322 | - |
dc.identifier.pmid | 37169835 | - |
dc.contributor.alternativeName | Kim, Beom Seok | - |
dc.contributor.affiliatedAuthor | 김범석 | - |
dc.contributor.affiliatedAuthor | 김형우 | - |
dc.contributor.affiliatedAuthor | 양재석 | - |
dc.contributor.affiliatedAuthor | 이주한 | - |
dc.contributor.affiliatedAuthor | 허규하 | - |
dc.citation.volume | 13 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 7682 | - |
dc.identifier.bibliographicCitation | SCIENTIFIC REPORTS, Vol.13(1) : 7682, 2023-05 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.